You are here: Home » Companies » News
Strong rural demand cushions volume weakness for Supreme Industries
Business Standard

Bharat Biotech aims at billion Covaxin doses a year, phase-3 trials in Oct

Firm also ties up with Washington University's school of medicine for intransal vaccine for Covid-19

Topics
Bharat Biotech | Vaccine | clinical trials

Aneesh Phadnis  |  Mumbai 



Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Phase-3 trials are pivotal and companies need to prove safety and efficacy of the vaccines in those trials

plans to start phase-3 of its indegeniously developed Covid-19 (Covaxin) in October and is in talks with partners to expand its manufacturing footprint to produce one billion doses annually.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Wed, September 23 2020. 18:44 IST

RECOMMENDED FOR YOU

.